Adjuvant treatment of postmenopausal women w/ hormone-receptor +ve early breast cancer; early breast cancer (+ve or unknown oestrogen or progesterone-receptor status) who have received 5 yr adjuvant tamoxifen therapy (extended adjuvant therapy). 1st-line treatment in postmenopausal women w/ hormone-dependent advanced breast cancer. Advanced breast cancer in women w/ natural- or artificially-induced postmenopausal status who have previously been treated w/ antioestrogens. Pre-op therapy in postmenopausal women w/ localised hormone-receptor +ve breast cancer.
Osteoporosis &/or bone fractures. Measure LH, FSH &/or estradiol levels prior to treatment. Avoid co-administration w/ tamoxifen, other anti-estrogens or estrogen-containing therapies. May affect ability to drive & use machines. Renal & severe hepatic impairment. Women of childbearing potential should use effective contraception. Not recommended in childn & adolescents ≤17 yr.
Sign Out
